Contraception
Volume 78, Issue 5 , Pages 384-391 , November 2008

Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters

  • Inka Wiegratz

      Affiliations

    • Center of Obstetrics and Gynecology, University Hospital of Frankfurt, D-60590 Frankfurt am Main, Germany
    • Corresponding Author InformationCorresponding author. Department of Obstetrics and Gynecology, J.W.Goethe University, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany. Tel.: +49 69 6301 5708; fax: +49 69 6301 5522.
    • ,
  • Skadi Stahlberg

      Affiliations

    • Center of Obstetrics and Gynecology, University Hospital of Frankfurt, D-60590 Frankfurt am Main, Germany
    • ,
  • Torsten Manthey

      Affiliations

    • Center of Obstetrics and Gynecology, University Hospital of Frankfurt, D-60590 Frankfurt am Main, Germany
    • ,
  • Nicole Sänger

      Affiliations

    • Center of Obstetrics and Gynecology, University Hospital of Frankfurt, D-60590 Frankfurt am Main, Germany
    • ,
  • Katrin Mittmann

      Affiliations

    • Jenapharm GmbH & Co KG, D-07745 Jena, Germany
    • ,
  • Evelyn Lange

      Affiliations

    • Jenapharm GmbH & Co KG, D-07745 Jena, Germany
    • ,
  • Uwe Mellinger

      Affiliations

    • Jenapharm GmbH & Co KG, D-07745 Jena, Germany
    • ,
  • Herbert Kuhl

      Affiliations

    • Center of Obstetrics and Gynecology, University Hospital of Frankfurt, D-60590 Frankfurt am Main, Germany

Received 14 April 2008 ,Revised 24 June 2008 ,Accepted 25 June 2008.

References 

  1. Wiegratz I, Kuhl H. Long-cycle treatment with oral contraceptives. Drugs. 2004;64:2447–2462
  2. Jung-Hoffmann C, Kuhl H. Pharmacokinetics and pharmacodynamics of oral contraceptive steroids: factors influencing steroid metabolism. Am J Obstet Gynecol. 1990;163:2183–2197
  3. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol. 2002;186:1142–1149
  4. Wiegratz I, Hommel HH, Zimmermann T, Kuhl H. Attitudes of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception. 2004;69:37–42
  5. Hamerlynck JVTH, Vollebregt JA, Doornebos CM, Muntendam P. Postponement of withdrawal bleeding in women using low-dose combined oral contraceptives. Contraception. 1987;35:199–205
  6. De Voogt WS. Postponement of withdrawal bleeding with a monophasic oral contraceptive containing desogestrel and ethinylestradiol. Contraception. 1991;44:107–112
  7. Kornaat H, Geerdink MH, Klitsie JW. The acceptance of a 7-week cycle with a modern low-dose oral contraceptive (Minulet). Contraception. 1992;45:121–127
  8. Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol. 2001;98:771–778
  9. Cachrimanidou AC, Hellberg D, Nilsson S, Waldenström U, Olsson SE, Sikström B. Long-interval treatment regimen with a desogestrel oral contraceptive. Contraception. 1993;48:205–216
  10. Cachrimanidou AC, Hellberg D, Nilsson S, von Schoultz B, Crona N, Siegbahn A. Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive. Contraception. 1994;50:153–165
  11. Loudon NB, Foxwell M, Potts DM, Guild AL, Short RV. Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cyclic pill regimen. BMJ. 1977;2:487–490
  12. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive: the Seasonale-301 Study Group. Contraception. 2003;68:89–96
  13. Anderson FD, Gibbons W, Portman D. Safety and efficacy of an extended regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception. 2006;73:229–234
  14. Birtch RL, Olatunbosun OA, Pierson RA. Ovarian follicular dynamics during conventional vs. continuous oral contraceptive use. Contraception. 2006;73:235–243
  15. Vercellini P, De Giorgi O, Mosconi P, Stellato G, Vicentini S, Crosignani PG. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril. 2002;77:52–61
  16. Kwiecin M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception. 2003;67:9–13
  17. Machado RB, Fabrini P, Machado Cruz A, Maia E, da Cunha Bastos A. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 μg) and gestodene (75 μg). Contraception. 2004;70:365–370
  18. Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. Venous thromboembolism and the pill. The WHO technical report on cardiovascular disease and steroid hormone contraception: state-of-the-art. Hum Reprod. 1998;13:2981–2983
  19. Herings RMC, Urquhart J, Leufkens HGM. Venous thromboembolism among new users of different oral contraceptives. Lancet. 1999;354:127–128
  20. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med. 2000;160:49–52
  21. Lidegaard O, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception. 2002;65:187–196
  22. Wiegratz I, Lee JH, Kutschera E, Winkler UH, Kuhl H. Effect of four oral contraceptives on hemostatic parameters. Contraception. 2004;70:97–106
  23. The Oral Contraceptive and Hemostasis Study Group. The effects of seven monphasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomised multicenter study. Contraception. 2003;67:173–185
  24. Kuhl H. Effects of progestins on haemostasis. Maturitas. 1996;24:1–19
  25. Winkler UH. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review. Am J Obstet Gynecol. 1998;179:S51–S61
  26. Norris LA, Bonnar J. The effect of oestrogen dose and progestin type on hemostatic changes in women taking low-dose oral contraceptives. Br J Obstet Gynaecol. 1996;103:261–267
  27. Spona J, Feichtinger W, Kindermann C, et al. Double-blind, randomized, placebo-controlled study on the effects of the monophasic oral contraceptive containing 30 μg ethinylestradiol and 2 mg dienogest on the hemostatic system. Contraception. 1997;56:67–75
  28. Task Force on Oral Contraceptives , WHO Special Programme of Research . A multicentre study of coagulation and hemostatic variables during oral contraception: variations with four formulations. Br J Obstet Gynaecol. 1991;98:1117–1128
  29. Winkler UH, Oberhoff C, Bier U, Schindler EA, Gillain D. Hemostatic effects of two oral contraceptives containing low doses of ethinyl estradiol and either gestodene or norgestimate: an open, randomised, parallel-group study. Int J Fertil. 1995;40:260–268
  30. Tans G, Curvers J, Middledorp S, et al. A randomised cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 2000;84:15–21
  31. Malm J, Laurell M, Dahlbäck B. Changes in the plasma levels of vitamin K-dependent protein C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol. 1988;68:437–443
  32. Kemmeren JM, Algra A, Meijers JCM, Bouma BN, Grobbee DE. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. Thromb Haemost. 2002;87:199–205
  33. Granata A, Sobbrio GA, D'Arrigo F, et al. Changes in the plasma levels of protein C and S in young women on low-dose oestrogen oral contraceptives. Clin Exp Obstet Gynecol. 1991;18:9–12
  34. Tans G, Bouma BN, Büller HR, Rosing J. Changes of hemostatic variables during oral contraceptive use. Semin Vasc Med. 2003;3:61–68
  35. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Koster T, Bertina RM, Vandenbroucke JP. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives. Thromb Haemost. 1998;80:382–387
  36. Brummel-Ziedins KE, Vossen CY, Butenas S, Mann KG, Rosendaal FR. Thrombin generation profiles in deep venous thrombosis. J Thromb Haemost. 2005;3:2497–2505
  37. Gomes MPV, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy. Arch Intern Med. 2004;164:1965–1976
  38. Tchaikovski S, Tan G, Rosing J. Venous thrombosis and oral contraceptives: current status. Women's Health. 2006;2:761–772
  39. Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ. 2000;321:1190–1195
  40. Bloemenkamp KWM. Epidemiology of oral contraceptive related thrombosis. Thromb Res. 2005;115S:1–6
  41. Seaman HE, de Vries CS, Farmer RDT. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study. Hum Reprod. 2003;18:522–526
  42. Wiegratz I, Jung-Hoffmann C, Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception. 1995;51:341–346
  43. Jung-Hoffmann C, Heidt F, Kuhl H. Effect of two oral contraceptives containing 30 mg ethinylestradiol and 75 mg gestodene or 150 mg desogestrel upon various hormonal parameters. Contraception. 1988;38:593–603
  44. Robinson GE, Burren T, Mackie IJ, et al. Changes in hemostasis after stopping the combined contraceptive pill. Implications for major surgery. BMJ. 1991;302:269–271

PII: S0010-7824(08)00373-9

doi: 10.1016/j.contraception.2008.06.015

Contraception
Volume 78, Issue 5 , Pages 384-391 , November 2008

Article Tools

* Image Usage & Resolution